403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Genomics Data Analysis Market Size To Surpass USD 28.74 Bn By 2034
| Report Coverage | Details |
| Market Size in 2025 | USD 7.91 Billion |
| Market Size by 2034 | USD 28.74 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 16.42% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | By Service / Workflow Type, By Technology / Platform, By Application, By End User, By Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Thermo Fisher Scientific Inc., Agilent Technologies Inc., F. Hoffmann-LA Roche Ltd., QIAGEN N.V., Pacific Biosciences of California Inc., 10x Genomics, Inc., PerkinElmer Inc., Invitae Corporation,Bio-Rad Laboratories Inc., Celerion,Myriad Genetics, Inc., SoftGenetics LLC |
For more information, visit the Nova One Advisor website or email the team at ... | Call us: +1 804 420 9370
What are the Major Drivers in the Genomics Data Analysis Market?
Advancements in sequencing technologies, rising demand for personalized medicine, and increasing government and private investment in genomics research. Additionally, the growing use of AI and bioinformatics tools for large-scale data interpretation and the expanding application of genomics in disease diagnosis and drug discovery are fueling market growth.
What are the Key trends in the Genomics Data Analysis Market in 2024?
- In January 2025, NVIDIA partnered with Illumina, Mayo Clinic, and Arch Institute to integrate its AI technologies into genomic research and drug discovery. This collaboration aims to advance healthcare innovation through generative and agentic AI, driving transformation across the $10 trillion global healthcare and life sciences sector. In November 2024, the World Health Organization (WHO) introduced guidelines for the ethical handling of human genomic data, covering its collection, access, use, and sharing. These principles aim to safeguard individual privacy, ensure fairness, and encourage responsible global collaboration in genomic research.
What is the Emerging Challenge in the Genomics Data Analysis Market?
Managing and securing the massive volumes of complex genomic data. Issues like data privacy, standardization, interoperability, and the high costs of computational infrastructure hinder efficient analysis. Additionally, the shortage of skilled bioinformaticians and regulatory uncertainties further complicate large-scale implementation and data sharing in genomics research.
- For Instance, According to the World Health Organization (WHO), while sequencing a whole genome may cost about USD 1,000, interpreting and analyzing that genomic data can be far more expensive, reaching nearly USD 1 million due to complex data processing and advanced analytical requirements.
Segmental Insights
By service/ workflow type analysis
What made the Variant Calling & Annotation Segment Dominant in the Genomics Data Analysis Market in 2024?
In 2024, the variant calling and annotation segment dominates the market due to its critical role in identifying genetic mutations linked to diseases and treatment responses. The growing use of next-generation sequencing
The data preprocessing & quality control segment is projected to grow at the fastest CAGR due to the increasing need for accurate, high-quality genomic datasets. As sequencing technologies generate massive data volumes, ensuring data integrity and eliminating errors becomes vital for reliable downstream analysis, clinical interpretation, and precision medicine applications, driving strong market demand.
- For Instance, In April 2024, Nonacus introduced a genomic profiling test combined with advanced bioinformatics and analysis software, enhancing data accuracy and clinical insights, which reflects the growing adoption of integrated genomic solutions in the market.
By technology/platform analysis
How did Next-generation Sequencing (NGS) Dominate the Genomics Data Analysis Market in 2024?
The next-generation sequencing (NGS) segment held the largest market share in 2024 due to its high throughput, cost efficiency, and ability to generate precise genomic data. Its wide application in clinical diagnosticsThe CRISPR segment is expected to grow at the fastest CAGR during the forecast period due to its precision, cost-effectiveness, and efficiency in gene editing and functional genomics. Its expanding use in therapeutics development, disease modelling, and personalized medicine, along with ongoing research advancements, is driving significant adoption across both clinical and research applications.
By application analysis
Why the Drug Discovery & Development Segment Dominated the Genomics Data Analysis Market in 2024?
The drug discovery & development segment held the highest market share in 2024 due to the growing insights to identify novel drug targets, predict therapeutic responses, and optimize treatment strategies. Pharmaceutical clinical trialsThe diagnostics and personalized medicine segment is expected to grow at the fastest CAGR during the forecast period due to increasing demand for early disease detection, precision therapies, and tailored treatment approaches. Advancements in genomics sequencing and bioinformatics are enabling clinicians to identify genetic variation more accurately, driving adoption in cancer diagnostics, rare disease screening, and preventive healthcare.
By end-user analysis
Why do the Pharmaceutical & Biotechnology Companies Segment dominate the Genomics Data Analysis Market in 2024?
The pharmaceutical & biotechnology company segment dominated the market with the major revenue share due to their extensive use of genomics data in drug discovery, biomarker
The hospital & diagnostic laboratory segment is expected to grow at the fastest CAGR during the forecast period due to rising adoption of genomics testing for disease diagnosis, treatment planning, and patient monitoring. Increasing integration of economic data into clinical workflows and expanding access to advanced sequencing technologies are enhancing precision care and driving demand across healthcare facilities.
By Regional Analysis
How is North America contributing to the Expansion of the Genomics Data Analysis Market?
North America dominated the market in 2024 due to strong research infrastructure, high investments in precision medicine, and the presence of major genomic technology companies. The region's advanced healthcare systems, government-backed genomics initiatives, and widespread adoption of next-generation sequencing technologies further strengthened its leadership position, driving innovation and large-scale implementation across clinical and research applications.
How is Asia-Pacific Accelerating the Genomics Data Analysis Market?
Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to increasing investments in genomic research, expanding healthcare infrastructure, and rising awareness of personalized medicine. Countries like China, Japan, and India are advancing genomic sequencing capabilities and bioinformatics adoption, supported by government initiatives and collaborations, driving regional growth and accelerating integration of genomics into clinical and research applications.
- For Instance, In March 2025, Illumina Inc. and Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center, completed sequencing 250,000 whole genomes under the Alliance for Genomic Discovery initiative. The data is being utilized to enhance drug target identification, advance therapeutic research, and accelerate clinical development efforts in precision medicine.
Top Companies in the Genomics Data Analysis Market
- Thermo Fisher Scientific Inc Agilent Technologies Inc. F. Hoffmann-LA Roche Ltd. QIAGEN N.V. Pacific Biosciences of California Inc. 10x Genomics, Inc. PerkinElmer Inc. Invitae Corporation Bio-Rad Laboratories Inc. Celerion Myriad Genetics, Inc SoftGenetics LLC Download Sample @
Recent Developments in the Genomics Data Analysis Market
- In February 2025, Ultima Genomics, Inc In January 2025, NVIDIA formed new partnerships aimed at revolutionizing the $10 trillion healthcare and life sciences sector by integrating AI, accelerated computing, and biological data. These collaborations focus on advancing genomic research, speeding up drug discovery, and introducing innovative AI-driven healthcare solutions.
You can place an order or ask any questions, please feel free to contact at ... | +1 804 441 9344
Related Report of Nova One Advisor:
- The global pharmacogenomics market The global AI in genomics market The global forensic genomics market The U.S. metagenomics market size The U.S. spatial genomics & transcriptomics market size
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the genomics data analysis market.
By Service / Workflow Type
- Variant calling & annotation Gene expression analysis Data preprocessing & quality control Secondary data analysis Tertiary/interpretation / visualization
By Technology / Platform
- Next Generation Sequencing (NGS) Whole Genome Sequencing (WGS) RNA Sequencing PCR & qPCR Microarray CRISPR based tools- Fastest
By Application
- Drug discovery & development Diagnostics / clinical diagnostics / personalized medicine Biomarker discovery Functional genomics / epigenomics / pathway analysis
By End User
- Pharmaceutical & biotechnology companies Hospitals & diagnostic laboratories Research & academic institutes
By Regional
- North America Europe Asia Pacific Latin America Middle East and Africa (MEA)
Immediate Delivery Available | Buy This Premium Research
About-Us
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
Web:Contact Us
USA: +1 804 420 9370
Email: ... For Latest Update Follow Us: LinkedIn Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Market Stats Insight | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment